Gilead: Primary Biliary Cholangitis Drug Seladelpar Approved in Boao Lecheng, Hainan.

On December 22nd, Gilead's primary biliary cholangitis drug Seladelpar was approved in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. It is suitable for adult patients with PBC who have inadequate response to UDCA monotherapy when used in combination with ursodeoxycholic acid, or as monotherapy for adult patients with PBC who cannot tolerate UDCA.